We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Randomized trials report the safety profile of vedolizumab in ulcerative colitis and Crohn's disease, highlighting tolerability in inflammatory bowel disease.
No takes yet. Share an insight, caveat, or question.
Colombel et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: